David Hava, PhD, is Chief Scientific Officer at Synlogic. He is a microbiologist and immunologist with more than 16 years of experience in the pharmaceutical industry leading platform and drug development programs. Before Synlogic, he was Chief Scientific Officer at Metera Pharmaceuticals, an early-stage company developing novel therapies for serious respiratory diseases. Previously, he was Chief Scientific Officer at Pulmatrix Inc, where he led research, development and clinical teams focused on the development of respiratory therapies in a novel dry powder delivery technology, called iSPERSE. In his role as CSO, he led the company’s therapeutic strategy to identify and prioritize drug targets and oversaw the advancement of multiple clinical programs into Phase 2 clinical development. Dave joined Pulmatrix in 2006 as 1 of the first Senior Scientists and was heavily involved in the early-stage research and development programs that identified and characterized several key aspects of the Pulmatrix technology. He earned his PhD in molecular biology and microbiology at Tufts University and completed his post-doctoral training studying immunology and host-pathogen interactions at Harvard Medical School. As a post-doctoral fellow Dave was awarded a Damon Runyan Cancer Research Fellowship. He has coauthored numerous manuscripts and abstracts focused on infectious disease, immunology, chronic lung diseases, and platform development.